Skip to content

Clinical Evaluation of "Zhi Sanzhen" Electroacupuncture for Cognitive Impairment in Alzheimer's Disease: A Series of Multiple-Crossover N-of-1 Trials

Clinical Evaluation of "Zhi Sanzhen" Electroacupuncture for Cognitive Impairment in Alzheimer's Disease: A Series of Multiple-Crossover N-of-1 Trials

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001432
Enrollment
Unknown
Registered
2025-07-20
Start date
2025-07-30
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

electro-acupuncture and basic treatment plan :On the basis of baseline treatment, patients will alternately receive interventions of 2 Hz continuous-wave electroacupuncture and 2 Hz/10 Hz disperse-den

Sponsors

The Affiliated TCM Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1)Patients meeting the 2023 NIA-AA clinical diagnostic criteria for Alzheimer's disease (AD) with Stage 3-4 manifestations; 2)Aged 50-85 years; 3)Right-handed; 4)Clinically stable condition; if using cognitive enhancers (e.g. Donepezil Hydrochloride or Memantine Hydrochloride) a stable dosage must have been maintained for at least 3 months.

Exclusion criteria

Exclusion criteria: 1)Individuals with visual or auditory impairments that preclude cooperation in completing assessments; 2)Presence of metal implants (e.g. stents pacemakers cochlear implants); 3)History of severe traumatic brain injury stroke migraine epilepsy familial psychiatric disorders or other neurological diseases affecting cognitive function; 4)Severe primary diseases involving the cardiovascular hepatic renal hematopoietic or endocrine systems; infectious/contagious diseases; bleeding tendency or hemorrhagic disorders; life-threatening conditions; or life expectancy <1 year; 5)History of fainting during needle procedures or at the sight of blood; 6)Substance abuse or addictive behaviors; 7)Current participation in other clinical trials or refusal to sign informed consent.

Design outcomes

Primary

MeasureTime frame
ADAS-cognitive subscale (ADAS-Cog);

Secondary

MeasureTime frame
amyloid beta related blood samples;Mini-mental State Examination(MMSE);Neuropsychiatric Inventory (NPI);

Countries

China

Contacts

Public ContactWenjia Lin

The Affiliated TCM Hospital of Guangzhou Medical University

2403523487@qq.com86 188 2640 4624

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026